Ownership and insider activity for Elicio Therapeutics, Inc. (ELTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers.
Price
| Price | $1.77 |
| Market Cap | $34M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.4M | $2.1M | $25.5M | $5.6M | $34.6M | $88.8M | $7.8M | $12.9M | $17.6M | $18.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $580378 | $485762 | $107000 | $440000 | $5.0M | $806000 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $2.1M | $2.6M | $25.7M | $6.1M | $40.3M | $91.2M | $10.7M | $16.3M | $20.7M | $19.3M |
| Property, Plant & Equipment | $6.6M | $6.2M | $17000 | $4.8M | $4.2M | $4.4M | $8.5M | $7.3M | $6.2M | $5.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $11.0M | $11.1M | $26.6M | $11.9M | $47.3M | $96.5M | $22.7M | $27.1M | $28.2M | $25.9M |
| Accounts Payable | $209516 | $37622 | $534000 | $11.2M | $5.6M | $4.7M | $2.8M | $4.4M | $1.0M | $672000 |
| Short-term Debt | $115582 | $122182 | 0 | $6.9M | $80.6M | $952000 | $692000 | 0 | $901000 | 0 |
| Total Current Liabilities | $1.1M | $1.1M | $7.4M | $26.6M | $107.4M | $11.3M | $6.9M | $9.8M | $11.5M | $8.1M |
| Long-term Debt | $5.3M | $5.2M | 0 | 0 | $635000 | 0 | 0 | 0 | $20.0M | $9.4M |
| Total Liabilities | $6.8M | $6.6M | $7.7M | $30.5M | $137.8M | $15.0M | $13.7M | $15.8M | $39.5M | $24.2M |
| Retained Earnings | $1.7M | $2.3M | -$39.8M | -$80.5M | -$160.6M | -$215.1M | -$107.0M | -$142.2M | -$194.1M | -$233.7M |
| Total Equity | $1.7M | $2.3M | $18.9M | -$18.6M | -$90.4M | $81.5M | $8.9M | $11.4M | -$11.3M | $1.6M |
| Total Debt | $5.4M | $5.3M | 0 | $10.8M | $85.0M | $4.7M | $7.5M | $6.9M | $26.0M | $14.5M |
| Net Debt | $4.0M | $3.3M | -$25.5M | $5.2M | $50.4M | -$84.1M | -$316000 | -$6.0M | $8.4M | -$4.1M |
| Working Capital | $959801 | $1.5M | $18.3M | -$20.5M | -$67.1M | $80.0M | $3.8M | $6.6M | $9.2M | $11.2M |
Financial Health
| Debt / Equity | 1.78 |
| Current Ratio | 2.77 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -13.92 |
Profitability
| Return on Equity | -1266.43% |
| Return on Invested Capital | -163.43% |
| Return on Assets | -120.78% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACTU · APLT · CRBP · CRDF · MIST · MOLN · NKTX
Explore sector: Healthcare · Biotechnology
More sections of ELTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks